Actively Recruiting
PPI Versus Histamine Antagnists as Adjuvant to Chemotherapy
Led by Sherief Abd-Elsalam · Updated on 2018-08-27
60
Participants Needed
1
Research Sites
487 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The study is a Comparative Clinical and Biochemical Study Evaluating the effect of Proton Pump I nhibitors versus histamine 2 Receptor antagonists as an adjuvant with chemotherapy in patients with Non-hodgkin Lymphoma.
CONDITIONS
Official Title
PPI Versus Histamine Antagnists as Adjuvant to Chemotherapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of DLBCL Lymphoma subtype
- No other coexisting medical conditions
You will not qualify if you...
- Pregnancy
- Peptic ulcer
- Severe cardiac disease
- Osteoporosis
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Sherief Abd-Elsalam
Cairo, Egypt
Actively Recruiting
Research Team
S
Sherief Abd-Elsalam, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here